Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway

DOI: 10.20892/j.issn.2095-3941.2017.0188

Keywords: Breast cancer, everolimus, next-generation sequencing, liquid biopsy, PI3K/AKT/mTOR

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text